Advenchen Laboratories, LLC

Quick facts

Phase 3 pipeline

• Digoxin (0.25mg) · Cardiovascular
  Digoxin inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing cardiac contractility while slowing atrioventricular node conduction.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Advenchen Laboratories, LLC portfolio CI brief
• Advenchen Laboratories, LLC pipeline updates RSS